Last updated: September 1, 2026
Aliskiren hemifumarate/hydrochlorothiazide was commercialized by Novartis as Tekturna HCT in the United States and Rasilez HCT in some international markets. The fixed-dose combination pairs aliskiren, a direct renin inhibitor, with hydrochlorothiazide, a thiazide diuretic, for hypertension.
The product’s commercial trajectory deteriorated after safety concerns surrounding aliskiren-containing regimens, weak differentiation from established antihypertensive combinations, and competition from low-cost generic ACE inhibitors, ARBs, calcium-channel blockers, beta blockers, and hydrochlorothiazide combinations. Novartis no longer treats the franchise as a major growth product. Generic and therapeutic-substitution pressure is high, while biosimilar risk is irrelevant because the product is a small-molecule drug.
What is aliskiren hemifumarate and hydrochlorothiazide?
Aliskiren inhibits renin, reducing the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide increases urinary sodium and water excretion. The combination lowers blood pressure through complementary mechanisms.
Tekturna HCT was supplied in several fixed-dose strengths, including combinations of aliskiren with hydrochlorothiazide at 150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg, according to the FDA prescribing information.[1]
| Attribute |
Product detail |
| Active ingredients |
Aliskiren hemifumarate and hydrochlorothiazide |
| Brand |
Tekturna HCT |
| Primary U.S. sponsor |
Novartis Pharmaceuticals |
| Therapeutic area |
Hypertension |
| Dosage form |
Oral tablets |
| FDA pathway |
New Drug Application |
| U.S. approval |
2009 |
| Drug class |
Direct renin inhibitor plus thiazide diuretic |
| Biosimilar exposure |
None |
| Main commercial substitutes |
Generic ARBs, ACE inhibitors, calcium-channel blockers, beta blockers, and thiazide combinations |
The product was intended for patients requiring more than one antihypertensive mechanism. In practice, physicians had many lower-cost and more familiar alternatives.
When did Tekturna HCT receive FDA approval?
The FDA approved Tekturna HCT in January 2009 for the treatment of hypertension.[2] The product was approved under NDA 021985. Aliskiren itself had been approved earlier as Tekturna, in 2007.
The regulatory profile changed after safety findings involving aliskiren used with renin-angiotensin system blockers.
Major FDA regulatory milestones
| Date |
Event |
Commercial significance |
| 2007 |
FDA approved Tekturna, aliskiren monotherapy |
Established the direct renin inhibitor franchise |
| 2009 |
FDA approved Tekturna HCT |
Added a fixed-dose combination product |
| 2011 |
ALTITUDE trial stopped early |
Raised concerns about aliskiren in high-risk diabetic and renal patients |
| 2012 |
FDA added restrictions and warnings for combined use with ACE inhibitors or ARBs |
Reduced addressable prescribing population |
| 2013 onward |
Generic antihypertensive competition intensified |
Increased price and formulary pressure |
The FDA label contraindicates use of aliskiren with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker in patients with diabetes. It also warns against such combinations in patients with moderate to severe renal impairment.[1]
What safety issues affected the aliskiren market?
The ALTITUDE trial evaluated aliskiren added to conventional therapy in patients with type 2 diabetes and renal impairment or cardiovascular disease. The trial was terminated early because aliskiren did not improve the primary endpoint and was associated with safety concerns, including renal impairment, hyperkalemia, hypotension, and stroke-related findings.[3]
The consequences extended beyond the specific population studied:
- Physicians became more cautious about the direct renin inhibitor class.
- Regulators restricted combination use with ACE inhibitors and ARBs.
- Formularies had less reason to favor aliskiren over established generic agents.
- The safety narrative weakened the commercial value of the entire Tekturna/Rasilez franchise.
Hydrochlorothiazide itself remained widely used. The principal commercial damage affected the aliskiren component and the branded fixed-dose combination.
How strong is the patent estate for aliskiren hydrochlorothiazide?
The patent estate was commercially meaningful during the launch period but is no longer a durable barrier to generic substitution. The product is a small-molecule combination, so its protection historically depended on compound, formulation, combination, and regulatory exclusivity rights rather than biologic data exclusivity.
Relevant protection categories
| Protection category |
Relevance to Tekturna HCT |
| Aliskiren compound patents |
Protected the active pharmaceutical ingredient |
| Salt and solid-state patents |
Covered forms such as aliskiren hemifumarate and related pharmaceutical compositions |
| Combination patents |
Covered aliskiren with hydrochlorothiazide |
| Formulation patents |
Could address tablet composition, stability, dissolution, or release characteristics |
| Method-of-use patents |
Could cover treatment of hypertension or patient subgroups |
| Regulatory exclusivity |
Applied during the period after NDA approval, separate from patent term |
Public patent records identify Novartis-related patents covering aliskiren compounds, pharmaceutical compositions, and combination products. The relevant U.S. patent term depends on the individual patent, terminal disclaimers, patent-term adjustment, and any patent-term extension. The original composition-of-matter protection for aliskiren has expired or is no longer a practical barrier to routine generic competition in the United States.
The FDA Orange Book remains the controlling source for current U.S. listed patents and exclusivity entries for NDA 021985.[4] Current commercial risk is therefore driven less by the existence of historical patents and more by whether any unexpired, listed formulation or method-of-use patent remains enforceable against a particular ANDA.
What is the Orange Book status of Tekturna HCT?
Tekturna HCT is an FDA-approved prescription product listed under Novartis’s NDA. The Orange Book records the reference listed drug and any associated patent or exclusivity information.[4]
The relevant legal distinction is between:
- The branded reference product.
- An ANDA applicant’s Paragraph IV certification.
- A patent that is listed in the Orange Book.
- A patent that is valid and infringed.
- A patent that actually delays generic launch.
An Orange Book listing does not establish validity. A generic applicant may challenge a listed patent through a Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed. The sponsor may then bring an infringement action within 45 days, potentially triggering a 30-month stay under the Hatch-Waxman Act.[5]
No major, continuing patent barrier has preserved premium pricing for the fixed-dose combination. The commercial product faces the same structural pressure as other mature oral antihypertensives.
Which companies are challenging aliskiren hydrochlorothiazide?
Generic competition has come from ANDA applicants and manufacturers of aliskiren/hydrochlorothiazide tablets. The U.S. generic market has included companies that manufacture, distribute, or market the product under abbreviated applications or authorized-generic arrangements.
The competitive field is fragmented because the product has limited current demand. Large generic manufacturers can supply the market, but smaller suppliers may enter or exit based on manufacturing economics, wholesaler contracts, and shortage conditions.
The key competitive threat is not a single branded rival. It is substitution across the entire hypertension market:
- Losartan/hydrochlorothiazide
- Valsartan/hydrochlorothiazide
- Irbesartan/hydrochlorothiazide
- Lisinopril/hydrochlorothiazide
- Amlodipine-based combinations
- Generic hydrochlorothiazide used with separate agents
These alternatives generally have stronger treatment familiarity, broader guideline use, and lower acquisition cost.
When does aliskiren hydrochlorothiazide lose exclusivity?
The product lost practical market exclusivity after the expiration of core aliskiren and combination protection and the emergence of generic competition. FDA approval in 2009 provided five years of new chemical entity exclusivity for the underlying NDA, subject to the regulatory treatment of the active ingredient and fixed-dose combination.[6]
Patent expiration should be assessed at the individual patent level rather than by assigning one date to the entire product. Different patents may cover the active ingredient, salt form, combination, formulation, or method of use. A generic company can often design around a formulation claim even when another patent remains in force.
Commercially, the relevant conclusion is clear: Tekturna HCT is a mature product with no credible long-term exclusivity runway comparable to a protected specialty drug.
How did the product’s financial trajectory develop?
Novartis did not generally report Tekturna HCT revenue as a separately disclosed line item. Public financial reporting grouped products within the Tekturna/Rasilez franchise or broader cardiovascular portfolio. This limits precise calculation of standalone product revenue, gross margin, and cash flow.
The trajectory followed four stages:
1. Launch and franchise expansion
The fixed-dose combination extended the Tekturna franchise after the 2007 launch of aliskiren monotherapy. Novartis sought to position direct renin inhibition as an alternative mechanism in a large hypertension market.
2. Slow adoption
Aliskiren did not displace generic ACE inhibitors or ARBs. The clinical value proposition was difficult to justify against inexpensive standard treatments, especially when blood-pressure control could be achieved through multiple established combinations.
3. Safety-driven contraction
The ALTITUDE outcome weakened physician confidence and narrowed the acceptable use of aliskiren. The label restrictions reduced opportunities for combination use with ACE inhibitors and ARBs, which are common components of hypertension treatment.
4. Mature generic erosion
Once generic alternatives became available, the product lost pricing power. Hydrochlorothiazide contributed little differentiation because it is inexpensive and widely available as a standalone generic.
| Financial driver |
Direction of impact |
| Generic competition |
Strong negative |
| ALTITUDE safety findings |
Strong negative |
| ACE/ARB combination restrictions |
Negative |
| Large hypertension patient population |
Positive market size |
| Direct renin inhibitor differentiation |
Limited positive |
| Low cost of substitute therapies |
Strong negative |
| Separate branded combination pricing |
Weak support |
| Biosimilar competition |
Not applicable |
Novartis’s later portfolio strategy concentrated capital on oncology, immunology, neuroscience, and selected cardiovascular assets with stronger growth prospects. A mature aliskiren combination did not fit that profile.
What generic entry risks exist for Tekturna HCT?
Generic entry risk is high. The principal scenarios are:
Immediate substitution
Where an FDA-approved generic is available and accepted by the payer, pharmacies can substitute it for the branded product. This is the most likely scenario in markets with active generic supply.
Price compression
Multiple ANDA holders can reduce wholesale acquisition cost and reimbursement. The branded product may retain limited demand among patients or prescribers with product-specific preferences, but that segment is unlikely to support historical pricing.
Supply-constrained pricing
A temporary shortage or manufacturer exit can produce short-term price increases. Such an event would reflect supply conditions, not durable intellectual-property strength.
Therapeutic substitution
Payers may steer patients to other antihypertensive combinations rather than to generic aliskiren/hydrochlorothiazide. This creates a larger threat than direct generic substitution because the alternatives include familiar, guideline-supported products.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate but not strategically strong. Aliskiren hemifumarate requires control of salt formation, crystallinity, impurity profile, particle characteristics, and tablet performance. Hydrochlorothiazide is a mature, widely manufactured active ingredient.
Potential technical barriers include:
- Consistent aliskiren hemifumarate solid-state properties.
- Content uniformity in low-dose combination tablets.
- Dissolution matching against the reference product.
- Stability of the fixed-dose formulation.
- Bioequivalence across multiple strengths.
- Supply-chain qualification for active ingredients and excipients.
These requirements can delay an individual generic applicant. They do not create a durable barrier for the overall market because the product is an oral small molecule with established analytical and manufacturing pathways.
How does Tekturna HCT compare with other antihypertensive combinations?
| Factor |
Aliskiren/HCTZ |
ARB/HCTZ |
ACE inhibitor/HCTZ |
| Mechanism |
Direct renin inhibition plus diuretic |
Angiotensin receptor blockade plus diuretic |
ACE inhibition plus diuretic |
| Generic availability |
Yes or historically available depending on market |
Broad |
Broad |
| Guideline familiarity |
Limited |
High |
High |
| Safety concerns |
Renal impairment, hyperkalemia, hypotension, combination restrictions |
Class-specific renal and potassium risks |
Cough, angioedema, renal and potassium risks |
| Formulary position |
Generally weak |
Generally strong |
Generally strong |
| Patent strength |
Mature and eroded |
Varies by product, mostly mature |
Mature and eroded |
| Commercial outlook |
Declining or limited |
Large generic market |
Large generic market |
The combination’s clinical and financial disadvantage is not hydrochlorothiazide. It is the relatively weak commercial position of aliskiren compared with ARBs and ACE inhibitors.
What is the outlook for revenue and market share?
Revenue exposure is concentrated in a declining mature-product base. The product has limited prospects for organic growth because:
- Hypertension treatment is highly genericized.
- Prescribers have extensive alternatives.
- Aliskiren safety restrictions limit use in high-risk populations.
- The combination has no biologic or specialty-drug pricing model.
- Generic manufacturers can compete on price.
- Novartis has stronger strategic priorities elsewhere.
Any remaining revenue is likely to come from residual branded prescriptions, markets with limited generic penetration, institutional purchasing, or temporary supply disruptions. The product should be valued as a low-growth or declining asset rather than as a platform for cardiovascular expansion.
Key Takeaways
- Aliskiren hemifumarate/hydrochlorothiazide was marketed by Novartis as Tekturna HCT.
- The FDA approved the product in 2009 for hypertension.
- The ALTITUDE trial materially damaged the aliskiren franchise and led to important FDA warnings and restrictions.
- Hydrochlorothiazide is commoditized and does not provide meaningful differentiation.
- Core patent and regulatory exclusivity have expired or eroded as commercial barriers.
- Generic and therapeutic-substitution risk is high.
- No biosimilar pathway applies because both active ingredients are small molecules.
- Novartis has not generally disclosed standalone Tekturna HCT revenue, limiting precise product-level financial modeling.
- The product’s financial trajectory is consistent with mature-brand decline, price compression, and declining strategic relevance.
FAQs
Is aliskiren hydrochlorothiazide still marketed in the United States?
FDA-approved reference and generic products may remain listed, but actual commercial availability depends on manufacturer supply, wholesaler status, and formulary demand. The product is no longer a major growth brand.
Can aliskiren hydrochlorothiazide be used with losartan?
Combining aliskiren with an ARB is restricted in patients with diabetes and is discouraged or restricted in patients with renal impairment. The FDA label contains the controlling warnings and contraindications.[1]
Does hydrochlorothiazide extend patent protection for aliskiren?
Hydrochlorothiazide does not automatically extend the patent term for aliskiren. A fixed-dose combination requires its own patent claims or other qualifying protection to create a separate enforceable barrier.
Is Tekturna HCT eligible for a 180-day generic exclusivity period?
A 180-day period may apply to a first ANDA applicant that makes a qualifying Paragraph IV certification, but eligibility depends on the specific ANDA, litigation history, forfeiture events, and FDA records. It should not be assumed solely from the existence of a generic product.
What is the principal investment risk for this product?
The principal risk is persistent revenue erosion from generic and therapeutic substitution, compounded by the restricted clinical positioning of aliskiren and the absence of a durable premium-pricing mechanism.
References
-
U.S. Food and Drug Administration. (2023). Tekturna HCT prescribing information. Novartis Pharmaceuticals Corporation.
-
U.S. Food and Drug Administration. (2009). FDA approval of Tekturna HCT, NDA 021985. Drugs@FDA.
-
Parving, H. H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Armbrecht, J., Holman, R. R., & ALTITUDE Investigators. (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine, 367(23), 2204-2213.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
-
U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the 180-day generic drug exclusivity. FDA.
